Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyoung-Ho Pyo

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2021
Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancerBeung-Chul Ahn, Jea-Woo So, Chun-Bong Synn, et al.
Frontiers in Chemistry|December 22, 2022
YH29407 with anti-PD-1 ameliorates anti-tumor effects <i>via</i> increased T cell functionality and antigen presenting machinery in the tumor microenvironmentDong Kwon Kim, Chun-Bong Synn, Seung Min Yang, et al.
Oncotarget|October 14, 2015
Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinomaHyo Song Kim, Sung-Moo Kim, Hyunki Kim, et al.
Frontiers in Oncology|March 31, 2022
Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell ImmunityWongeun Lee, Dong Kwon Kim, Chun-Bong Synn, et al.
Molecular Cancer Therapeutics|December 5, 2024
Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with PembrolizumabDong Kwon Kim, Chun-Bong Synn, Wongeun Lee, et al.
Clinical & Translational Immunology|January 10, 2022
SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer modelsChun-Bong Synn, Sung Eun Kim, Hee Kyu Lee, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2021
Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancerBeung-Chul Ahn, Jea-Woo So, Chun-Bong Synn, et al.
Frontiers in Chemistry|December 22, 2022
YH29407 with anti-PD-1 ameliorates anti-tumor effects <i>via</i> increased T cell functionality and antigen presenting machinery in the tumor microenvironmentDong Kwon Kim, Chun-Bong Synn, Seung Min Yang, et al.
Oncotarget|October 14, 2015
Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinomaHyo Song Kim, Sung-Moo Kim, Hyunki Kim, et al.
Frontiers in Oncology|March 31, 2022
Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell ImmunityWongeun Lee, Dong Kwon Kim, Chun-Bong Synn, et al.
Molecular Cancer Therapeutics|December 5, 2024
Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with PembrolizumabDong Kwon Kim, Chun-Bong Synn, Wongeun Lee, et al.
Clinical & Translational Immunology|January 10, 2022
SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer modelsChun-Bong Synn, Sung Eun Kim, Hee Kyu Lee, et al.
Pageof 6